S-1: Actuate Therapeutics Files for IPO, Eyes Nasdaq Listing Under 'ACTU'

Actuate Therapeutics, a clinical-stage biopharmaceutical company, has filed an S-1 registration statement for an initial public offering, planning to list its common stock on the Nasdaq Capital Market under the ticker symbol 'ACTU'.

Summary

• Actuate Therapeutics, a clinical-stage biopharmaceutical company, has filed an S-1 registration statement for an initial public offering.
• The company is focused on developing therapies for difficult-to-treat cancers by inhibiting glycogen synthase kinase-3 (GSK-3).
• Their lead drug candidate, elraglusib, is being evaluated in a Phase 2 trial for metastatic pancreatic cancer.
• The company has applied to list its common stock on the Nasdaq Capital Market under the ticker symbol 'ACTU'.
• Top-line results from the ongoing Phase 2 trial are expected in the first quarter of 2025.
• A clinical candidate tablet (Elraglusib Oral Tablet) has been developed and selected and a first in human dose escalation study using Elraglusib Oral Tablet could begin in the fourth quarter of 2024.
• The company intends to use the net proceeds from this offering for clinical trials, product development, research and development, clinical manufacturing, working capital and other general corporate purposes.
• Preliminary analysis of interim data from Actuate-1801 Part 3B demonstrates a mOS of 12.2 months in the elraglusib combination therapy arm versus 7.3 months in the GnP control group arm (HR=0.60; log-rank p=0.012).

Sentiment

Score: 7

Explanation: The document presents a balanced view, highlighting both the potential of the company's lead drug candidate and the risks associated with its development and commercialization. The positive clinical data and regulatory designations are encouraging, but the company's financial situation and dependence on a single product candidate temper the overall sentiment.

Positives

• Elraglusib has shown promising results in early clinical trials, including a median overall survival (mOS) of 15.3 months in a Phase 2 study.
• The company has Fast Track and Orphan Drug Designations from the FDA for pancreatic cancer.
• The company has a broad pipeline in a molecule approach with elraglusib, targeting multiple cancer types and dosage forms.
• The company has a research and development collaboration with Lantern Pharma to leverage their artificial intelligence platform.
• The company has completed a Phase 1 healthy volunteer study showing very favorable (>50%) bioavailability after a single dose of Elraglusib Oral Liquid.

Negatives

• The company has a limited operating history and has incurred significant operating losses since its inception.
• The company's financial condition raises substantial doubt about its ability to continue as a going concern.
• The company currently depends entirely on the success of elraglusib, which is its only product candidate.
• The company's current Phase 2 study design cannot be used to support accelerated approval.
• The company's current elraglusib drug substance (DS) manufacturer is in China, and it is unknown how current or future geopolitical relationships with China may affect our ability to obtain DS.

Risks

• The company may not be able to generate revenue or become profitable.
• Clinical trials may not yield sufficiently conclusive results for regulatory agencies to approve the use of the company's products.
• The company may experience delays or difficulties in the enrollment of subjects to its clinical trials.
• The company may not be successful in its efforts to investigate elraglusib in additional indications.
• The company may face significant competition from other biotechnology and pharmaceutical companies.
• The company will require substantial additional capital to finance its operations and fund its clinical trials.
• The company's principal stockholders have significant control over the company.

Future Outlook

The company plans to advance elraglusib through clinical trials, seek regulatory approval, and commercialize it in a broad list of advanced cancer indications, initially in patients with refractory disease and with an initial focus on metastatic pancreatic cancer.

Management Comments

• Daniel Schmitt, our chief executive officer and founder, and Dr. Andrew Mazar, our scientific co-founder and chief operating officer, have more than 60 years of combined experience in the management of biotechnology companies and healthcare investing.
• Mr. Schmitt has led and contributed to the successful development and launch of multiple pharmaceutical and health technology products and executed over approximately $1.0 billion in milestone value through licensing, acquisition, and development deals.
• Dr. Mazar has shepherded eleven drugs from discovery stage through Phase 2 and Phase 3 trials.

Industry Context

The document highlights the competitive landscape of the biopharmaceutical industry, particularly in oncology, noting that the development and commercialization of new drug products is highly competitive. It mentions the presence of major pharmaceutical companies, specialty biopharmaceutical companies, and biotechnology companies, as well as academic institutions and research organizations, all vying for market share. The document also acknowledges the trend toward managed healthcare and cost-containment initiatives, which are putting pressure on drug pricing and usage.

Comparison to Industry Standards

• The mOS in patients with mPDAC is 9-11 months and the ability to extend survival by even a few months would be considered meaningful in this patient population.
• The mOS of 7.7 months in Part 1 benchmarks favorably with mOS 8-10 months for other active single agents evaluated in Phase 1.
• The elraglusib mOS of 11.9 months for the ITT compares favorably with the mOS of 11.2 months for FOLFIRINOX, the other first line regimen used for patients with mPDAC or more recently with irinotecan liposomal injection (Onivyde) (mOS=11.1 months).
• The FDA recently approved irinotecan liposomal injection (Onivyde) for the treatment of mPDAC based on the mOS=11.1 months in the NAPOLI-3 trial.

Stakeholder Impact

• Shareholders: Potential for increased value if the company is successful, but also risk of dilution and loss of investment.
• Employees: Potential for job creation and career advancement, but also risk of job loss if the company is not successful.
• Patients: Potential for new and effective treatments for difficult-to-treat cancers.
• Suppliers: Potential for increased business if the company is successful.
• Creditors: Risk of not being repaid if the company is not successful.

Next Steps

• Complete the ongoing Elraglusib Injection Phase 2 mPDAC trial (Actuate-1801 Part 3B).
• Complete the existing pediatric refractory cancer Phase 1 dose escalation trial and continue exploring development opportunities and potentially initiate the Phase 2 portion of this study in patients with refractory Ewing sarcoma (Actutate-1902).
• Satisfy the company's funding commitments for ongoing IIT studies for the use of Elraglusib Injection with other chemotherapy agents to treat mPDAC and a separate trial to treat recurrent salivary gland cancer.
• Finalize development plans for and potentially initiate and complete a Phase 1 dose escalation study with Elraglusib Oral Tablet in patients with advanced, refractory solid cancer.
• Finalize development plans for and potentially initiate a Phase 2 study with Elraglusib Oral Tablet in refractory metastatic melanoma.
• Initiate a Phase 3 mPDAC trial and finalize development plans for an additional randomized Phase 2 trial in metastatic refractory colorectal cancer.

Key Dates

Keywords

elraglusib, pancreatic cancer, GSK-3, clinical trials, biopharmaceutical, oncology, metastatic, FDA, orphan drug, Ewing sarcoma